Endura

Endura Therapeutics is an early-stage biotechnology company based in South San Francisco, California, focused on developing a novel class of small molecule drugs that target disease at the transcript level. The company's proprietary TRANSCEND platform utilizes 'Enduring Chemistry' to design small molecules that form permanent covalent bonds with messenger RNA (mRNA), effectively blocking the translation of disease-causing proteins. This approach aims to address 'undruggable' targets, such as disordered proteins and gene-driven pathologies, with the precision of genetic therapies but the convenience of a small molecule pill. Founded in 2024 by a team of experts from Novartis, Stanford, and Atomic AI, Endura is currently in stealth mode, advancing a pipeline in oncology and neurodegeneration.